Skip to content
Therapy But Better – Lifestyle
Author:
Biodexa Pharmaceuticals PLC
Result of Annual General Meeting
June 30, 2026
Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants
June 30, 2026
Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress
June 29, 2026
Postponement and Re-scheduling of Annual General Meeting
June 17, 2026
Biodexa issues letter to Shareholders
May 14, 2026
Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies
April 2, 2026
Preliminary Results for the Year Ended 31 December 2025
March 30, 2026
Biodexa Announces Support for Life’s a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients
March 27, 2026
Preliminary Results for the Year Ended 31 December 2025
March 26, 2026
Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group
March 23, 2026
1
2
Next Page
→